blood basophils greater than or equal to 6 percent and blood eosinophils greater than or equal to 6 percent) which provided for the development of a clinical staging system: Stage I with none or one factor and a two-year survival rate of 100 percent; Stage II with two or three factors an...
The disease-specific survival rate for CML was higher for incident cases than for cases diagnosed before February 1, 2002, both at 3, 5 and 10 years (Table 1). Kaplan–Meier analysis showed a difference in survival rate between cases diagnosed before and after imatinib introduction, starting ...
Dr Cortes on the Phase 4 BYOND Study in Previously Treated Patients With CML Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC Dr Adige on Improving QOL Post–Breast Cancer Treatment Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibit...
Skip to main contentSkip to article
Patients with refractory large B-cell lymphoma who were treated with axicabtagene ciloleucel (axi-cel; Yescarta) had a 3-year overall survival (OS) rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial. The median duration of follow-up was 39.1 month...
Poor outcomes can be associated with the asymptomatic nature of early-stage disease, typically late clinical diagnosis, and high metastatic activity of the primary tumor resulting in a 5-year survival rate of only 6% [2], [3]. Even in cases where surgical intervention of localized disease is ...
Despite improved patient outcome using tyrosine kinase inhibitors (TKIs), chronic myeloid leukaemia (CML) patients require life-long treatment due to leukaemic stem cell (LSC) persistence. LSCs reside in the bone marrow (BM) niche, which they modify to t
The approval of the Bcr-Abl inhibitor, imatinib (Glivec®) for clinical use in 2001 led to a significant improvement in the survival rate and prognosis of patients with CML (4). However, 10-15% of patients develop resistance to imatinib or to new-generation Bcr-Abl inhibitors (5). The...
Among men, African Americans have the highest rate, more than 2.7 times greater than the rate for non-Hispanic white men. Incidence rates generally increase with age in all racial and ethnic groups. Cancer of the esophagusis common cancer in developing countries of the world, where most tumors...
The relapse-free survival (RFS) rate was 77% in the cohort of patients who received Orca-T vs 62% in the cohort of patients who received PTCy (HR, 0.5; 95% CI, 0.3-0.9). Furthermore, the non-relapse mortality (NRM) rates with Orca-T and PTCy were 3% and 16%, respectively (H...